Aldeyra Therapeutics, Inc. (ALDX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALDX SEC filings page.
This page shows Aldeyra Therapeutics, Inc. (ALDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Aldeyra remains a development-stage business: spending is shrinking, losses narrowed, but its balance sheet is steadily being consumed.
In FY2025, the net loss of$33.8M nearly matched operating cash outflow of$33.3M , so reported earnings are translating into cash use rather than being distorted mainly by non-cash items. The operating loss narrowed in FY2025 while R&D fell46.8% , pointing to spending reduction—not commercial scale—as the clearer mechanism.
Assets fell from
The current ratio fell from 5.6x to 2.6x, indicating less current-asset coverage for each dollar of current liabilities. Reported liquidity equaled 25.2 months of latest annual operating outflow, a balance-to-outflow comparison that sits alongside a steadily thinner short-term cushion.
Financial Health Signals
Aldeyra Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Aldeyra Therapeutics, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
Aldeyra Therapeutics, Inc. reported a net loss of $33.8M while operations used $33.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Aldeyra Therapeutics, Inc. reported an operating loss of $35.3M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Aldeyra Therapeutics, Inc.'s EBITDA was -$5.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Aldeyra Therapeutics, Inc. reported a net loss of $5.5M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Aldeyra Therapeutics, Inc. earned -$0.09 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Aldeyra Therapeutics, Inc. held $45.1M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Aldeyra Therapeutics, Inc.'s quarterly ROE was -14.4% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Aldeyra Therapeutics, Inc. invested $3.5M in research and development in Q2 2026. This represents a decrease of 59.0% from the same quarter a year earlier. Against the prior quarter it is up 44.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
ALDX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $3.5M-59.0% | $2.4M-67.5% | N/A | $5.4M-56.3% | $8.5M-43.2% | $7.4M+20.1% | N/A | $12.4M+78.7% |
| SG&A Expenses | $2.4M+42.2% | $1.1M-62.1% | N/A | $2.6M-30.5% | $1.7M-45.2% | $3.0M-6.4% | N/A | $3.7M+42.8% |
| Operating Income | -$5.9Mn/m | -$3.5Mn/m | N/A | -$8.0Mn/m | -$10.2Mn/m | -$10.4Mn/m | N/A | -$16.1Mn/m |
| EBITDA | -$5.8Mn/m | -$3.5Mn/m | N/A | -$7.9Mn/m | -$10.1Mn/m | -$10.4Mn/m | N/A | -$16.1Mn/m |
| Interest Expense | $23-100.0% | $469K-3.1% | N/A | $476K-0.7% | $471K-1.5% | $484K-3.0% | N/A | $479K-11.0% |
| Net Income | -$5.5Mn/m | -$3.5Mn/m | N/A | -$7.7Mn/m | -$9.8Mn/m | -$9.9Mn/m | N/A | -$15.1Mn/m |
| EPS (Basic) | -$0.09n/m | -$0.06n/m | -$0.10n/m | -$0.13n/m | -$0.16n/m | -$0.17n/m | -$0.27n/m | -$0.25n/m |
| EPS (Diluted) | -$0.09n/m | -$0.06n/m | -$0.10n/m | -$0.13n/m | -$0.16n/m | -$0.17n/m | -$0.27n/m | -$0.25n/m |
| Diluted Shares (Avg) | 60M+0.5% | 60M+0.7% | N/A | 60M+1.0% | 60M+1.1% | 60M+0.8% | N/A | 60M+0.9% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
ALDX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $47.5M-44.0% | $66.5M-28.7% | $72.1M-31.1% | $77.8M-33.7% | $85.0M-32.6% | $93.2M-34.0% | $104.6M-29.5% | $117.3M-20.3% |
| Current Assets | $47.4M-44.0% | $66.3M-28.5% | $71.8M-31.0% | $77.5M-33.6% | $84.6M-32.7% | $92.7M-34.2% | $104.1M-29.6% | $116.7M-20.7% |
| Cash & Equivalents | $45.1M+9.3% | $65.0M+29.1% | $70.0M+28.5% | $59.3M-12.9% | $41.2M-41.9% | $50.4M-50.9% | $54.5M-61.8% | $68.1M-52.5% |
| Short-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $16.0M-64.2% | $40.7M-17.5% | $39.7M+30.0% | $46.6Mn/m | $44.6Mn/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $9.7M-67.5% | $24.3M-17.8% | $27.8M-17.2% | $28.6M-11.4% | $29.7M+7.0% | $29.6M+6.1% | $33.6M+17.8% | $32.2M+32.7% |
| Current Liabilities | $9.7M-67.3% | $24.3M+70.3% | $27.8M+49.5% | $28.5M+66.1% | $29.5M+7.0% | $14.3M-34.1% | $18.6M-16.4% | $17.2M-20.6% |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $0-100.0% | $73K-99.5% | $143K+3.3% | $15.3M+146.7% | $15.0M+139.2% | $15.1M+467.1% |
| Long-Term Debt | N/A | $0-100.0% | $0-100.0% | $0-100.0% | $0n/m | $15.1Mn/m | $15.0Mn/m | $15.0M+464.5% |
| Total Equity | $37.9M-31.5% | $42.2M-33.7% | $44.3M-37.7% | $49.2M-42.1% | $55.3M-43.8% | $63.6M-43.9% | $71.0M-40.7% | $85.1M-30.8% |
| Retained Earnings | -$492.9Mn/m | -$487.4Mn/m | -$484.0Mn/m | -$477.5Mn/m | -$469.8Mn/m | -$460.0Mn/m | -$450.1Mn/m | -$434.3Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
ALDX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.6Mn/m | -$5.1Mn/m | -$5.3Mn/m | -$7.0Mn/m | -$8.6Mn/m | -$12.5Mn/m | -$12.0M-2505.3% | -$8.0Mn/m |
| Depreciation & Amortization | $71K+13.5% | $67K+9.3% | $65K+1.2% | $64K+1.1% | $62K+1.1% | $61K+0.5% | $64K-3.2% | $63K-3.1% |
| Stock-Based Compensation | $1.6M+735.9% | -$988K-144.4% | N/A | $2.6M-20.0% | $197K-89.8% | $2.2M+43.6% | N/A | $3.2M+308.7% |
| Investing Cash Flow | -$23Kn/m | $0-100.0% | $16.0Mn/m | $25.0M+375.0% | -$554Kn/m | $7.3Mn/m | -$1.6Mn/m | $5.3Mn/m |
| Financing Cash Flow | -$15.3Mn/m | $71K-92.9% | $0-100.0% | $121Kn/m | $0n/m | $1.0M+5412.7% | $8Kn/m | -$197Kn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
ALDX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -14.4%+3.3pp | -8.2%+7.4pp | N/A | -15.6%+2.2pp | -17.7%-0.5pp | -15.6%-8.5pp | N/A | -17.8%-11.1pp |
| Return on Assets | -11.5%0.0pp | -5.2%+5.5pp | N/A | -9.9%+3.0pp | -11.5%+1.9pp | -10.7%-4.9pp | N/A | -12.9%-7.3pp |
| Current Ratio | 4.91+2.0x | 2.72-3.8x | 2.58-3.0x | 2.72-4.1x | 2.86-1.7x | 6.490.0x | 5.59-1.0x | 6.800.0x |
| Debt-to-Equity | N/A | 0.00-0.2x | 0.00-0.2x | 0.00-0.2x | 0.000.0x | 0.24+0.2x | 0.21+0.2x | 0.18+0.2x |
| Liabilities-to-Equity | 0.25-0.3x | 0.58+0.1x | 0.63+0.2x | 0.58+0.2x | 0.54+0.3x | 0.47+0.2x | 0.47+0.2x | 0.38+0.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Aldeyra Therapeutics, Inc. ALDX | FY2025 | N/A | -$33.8M | N/A | $38.9M | — |
| Contineum Therapeutics, Inc. CTNM | FY2025 | N/A | -$60.0M | N/A | $312.6M | — |
| Tectonic Therapeutic, Inc. TECX | FY2025 | N/A | -$74.2M | N/A | $392.4M | — |
| MBX Biosciences, Inc. MBX | FY2025 | N/A | -$87.0M | N/A | $2.3B | — |
| 4D Molecular Therapeutics, Inc. FDMT | FY2025 | $85.2M | -$140.1M | N/A | $596.6M | 72/100 |
Where Aldeyra Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Aldeyra Therapeutics, Inc. profitable?
No, Aldeyra Therapeutics, Inc. (ALDX) reported a net loss of $33.8M in fiscal year 2025.
What is Aldeyra Therapeutics, Inc.'s EBITDA?
Aldeyra Therapeutics, Inc. (ALDX) had EBITDA of -$35.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Aldeyra Therapeutics, Inc. have?
As of fiscal year 2025, Aldeyra Therapeutics, Inc. (ALDX) had $70.0M in cash and equivalents against $0 in long-term debt.
What is Aldeyra Therapeutics, Inc.'s return on equity (ROE)?
Aldeyra Therapeutics, Inc. (ALDX) has a return on equity of -76.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aldeyra Therapeutics, Inc.'s operating cash flow?
Aldeyra Therapeutics, Inc. (ALDX) recorded an outflow of $33.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aldeyra Therapeutics, Inc.'s total assets?
Aldeyra Therapeutics, Inc. (ALDX) had $72.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aldeyra Therapeutics, Inc. spend on research and development?
Aldeyra Therapeutics, Inc. (ALDX) invested $25.7M in research and development during fiscal year 2025.
What is Aldeyra Therapeutics, Inc.'s current ratio?
Aldeyra Therapeutics, Inc. (ALDX) had a current ratio of 2.58 as of fiscal year 2025, which is generally considered healthy.
What is Aldeyra Therapeutics, Inc.'s debt-to-equity ratio?
Aldeyra Therapeutics, Inc. (ALDX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Aldeyra Therapeutics, Inc.'s liabilities-to-equity ratio?
Aldeyra Therapeutics, Inc. (ALDX) had a liabilities-to-equity ratio of 0.63 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Aldeyra Therapeutics, Inc.'s return on assets (ROA)?
Aldeyra Therapeutics, Inc. (ALDX) had a return on assets of -47.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aldeyra Therapeutics, Inc.'s P/E ratio?
Aldeyra Therapeutics, Inc. (ALDX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $38.9M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Aldeyra Therapeutics, Inc.'s price-to-sales ratio?
Aldeyra Therapeutics, Inc. (ALDX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $38.9M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Aldeyra Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Aldeyra Therapeutics, Inc. (ALDX) held $70.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $33.3M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Aldeyra Therapeutics, Inc.'s Piotroski F-Score?
Aldeyra Therapeutics, Inc. (ALDX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aldeyra Therapeutics, Inc.'s earnings high quality?
Aldeyra Therapeutics, Inc. (ALDX) reported a net loss of $33.8M while operations used $33.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aldeyra Therapeutics, Inc. cover its interest payments?
Aldeyra Therapeutics, Inc. (ALDX) reported an operating loss of $35.3M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.